Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 3 2Phase 1/2 1

Status

Completed 6Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Solid Tumor, Adult 1Neoplasm Metastasis 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Completed × necitumumab × Clear all
NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Eli Lilly and Company

Phase 1 Completed
29 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03360734 2021-07-12

GATTO

Glycotope GmbH

Phase 1 Completed
50 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT02451930 2020-10-05

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Eli Lilly and Company

Phase 1 Completed
71 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02411591 2020-07-09

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1 Completed
66 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01088464 2017-02-03

Study of IMC-11F8 in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
15 enrolled 22 charts
Tumor-Agnostic

Neoplasms

NCT00801177 2010-10-13

Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Eli Lilly and Company

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡